Abstracts

716 – Polypharmacy Trajectories Among Older People in the SHCS: A Longitudinal Analysis From 2016 to 2024

Background Polypharmacy, defined as the use of >5 non-HIV medications, is common in older people with HIV (PWH). Polypharmacy has been evaluated mostly in cross-sectional studies which do not inform on patterns of medications use over time. This study aimed to determine polypharmacy trajectories and identify associated predictors among older PWH in the Swiss HIV…

456 – GrimAge Clock Corresponds to Accelerated Brain Aging and Executive Dysfunction in People With HIV

Background DNA methylation (DNAm) clocks can measure accelerated biological aging caused by HIV. However, newer DNAm clocks sensitive to disease and mortality, and predictive of future epigenetic changes, have not been compared to brain health biomarkers in the context of virally suppressed HIV. Methods People with HIV (PWH) and without HIV (PWoH) underwent a blood…

203 – Galectin-9 Enables HIV Infection of Resting CD4+ T Cells and Promotes Latent Reservoir Expansion

Background The mechanisms underlying latent HIV reservoir establishment and maintenance remain poorly understood and a hinderance to an HIV cure. Elevated plasma levels of galectin-9 (Gal-9), a β-galactoside-binding lectin, predicts slower intact proviral DNA decay in people with HIV (PWH) on antiretroviral therapy (ART) and associates with increased gut mucosal SIV burden. Here, we investigated…

783 – Decreased Serum Drug Levels of Second-Line Antimycobacterial Agents in People With HIV

Background HIV has been associated with multidrug-resistant tuberculosis (MDR-TB), possibly due to lower TB drug concentrations that can favor the development of resistance. To explore this, we compared serum drug levels of second-line antimycobacterials in people being treated for MDR-TB with and without HIV. Methods The PREEMPT study included adult participants from Brazil and India…

589 – MDL-001, a Novel Oral Thumb-1 Polymerase Inhibitor, Shows Efficacy in HCV/HBV In Vitro and In Vivo

Background MDL-001 is a first-in-category oral direct-acting non-nucleoside inhibitor that binds a previously underexploited allosteric pocket in the Thumb-1 domain of viral polymerase. We assessed inhibition of hepatitis C virus (HCV) and hepatitis B virus (HBV) in mono- and co-infection in vitro, established HCV and HBV proof-of-concept (POC) in vivo, and summarized nonclinical pharmacokinetic (PK)…

558 – HIV-1 Drug Resistance and Treatment Outcomes in Experienced Kenyan Persons in the Dolutegravir Era 

Background With expanding global antiretroviral therapy (ART) access, integrase strand transfer inhibitors (INSTIs) and protease inhibitors (PIs) are increasingly used in ART-experienced persons. Current data on the extent and impact of resistance in this population are limited yet needed to inform future ART options. Methods We reviewed clinical and genotyping records of ART-experienced persons in…

295 – Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection

Background Broadly neutralizing antibodies (bNAbs) are promising HIV-1 immunoprophylactics, conferring protection in both preclinical and clinical studies. To overcome viral resistance to individual antibodies, bispecific bNAbs have been generated to increase breadth. We previously established that the bispecific 10E8.4/iMab, which targets the membrane-proximal external region of HIV envelope and the CD4 receptor, protects against high-dose…

1051 – Impact of US Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries

Background The freezing of U.S. government (USG) foreign assistance funds on January 20, 2025, marked a pivotal shift for HIV programs globally, resulting in clinic closures, staff layoffs and interruptions in HIV-related service delivery and research. To document the status of HIV-related service delivery in mid-2025, the International epidemiology Databases to Evaluate AIDS (IeDEA) research…